$KYMR Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Kymera Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Kymera Therapeutics, Inc.. Get notifications about new insider transactions in Kymera Therapeutics, Inc. for free.
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 17 2021 | KYMR | Kymera Therapeutic ... | Ridloff Elena | Director | Option Exercise | A | 49.10 | 20,063 | 985,093 | 20,063 | |
| Jun 17 2021 | KYMR | Kymera Therapeutic ... | Ridloff Elena | Director | Option Exercise | A | 49.10 | 20,063 | 985,093 | 20,063 | |
| Jun 09 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Option Exercise | M | 2.08 | 5,752 | 11,964 | 197,734 | |
| Jun 09 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Option Exercise | M | 2.08 | 270 | 562 | 203,486 | |
| Jun 09 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Option Exercise | M | 2.08 | 12,724 | 26,466 | 203,756 | |
| Jun 09 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Sell | S | 50.02 | 5,752 | 287,721 | 412,199 | 418 K to 412.2 K (-1.38 %) |
| Jun 09 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Buy | M | 2.08 | 5,752 | 11,964 | 417,951 | 412.2 K to 418 K (+1.40 %) |
| Jun 09 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Sell | S | 50.00 | 270 | 13,500 | 412,199 | 412.5 K to 412.2 K (-0.07 %) |
| Jun 09 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Buy | M | 2.08 | 270 | 562 | 412,469 | 412.2 K to 412.5 K (+0.07 %) |
| Jun 09 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Sell | S | 50.14 | 12,724 | 638,040 | 412,199 | 424.9 K to 412.2 K (-2.99 %) |
| Jun 09 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Buy | M | 2.08 | 12,724 | 26,466 | 424,923 | 412.2 K to 424.9 K (+3.09 %) |
| May 14 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Option Exercise | M | 2.08 | 8,245 | 17,150 | 216,480 | |
| May 14 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Sell | S | 50.05 | 8,245 | 412,677 | 397,199 | 405.4 K to 397.2 K (-2.03 %) |
| May 14 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Buy | M | 2.08 | 8,245 | 17,150 | 405,444 | 397.2 K to 405.4 K (+2.08 %) |
| Apr 26 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Option Exercise | M | 2.08 | 2,768 | 5,757 | 224,725 | |
| Apr 26 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Option Exercise | M | 2.08 | 680 | 1,414 | 227,493 | |
| Apr 26 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Option Exercise | M | 2.08 | 10,959 | 22,795 | 228,173 | |
| Apr 26 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Sell | S | 40.18 | 2,768 | 111,229 | 397,199 | 400 K to 397.2 K (-0.69 %) |
| Apr 26 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Buy | M | 2.08 | 2,768 | 5,757 | 399,967 | 397.2 K to 400 K (+0.70 %) |
| Apr 26 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Sell | S | 40.01 | 680 | 27,208 | 397,199 | 397.9 K to 397.2 K (-0.17 %) |
| Apr 26 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Buy | M | 2.08 | 680 | 1,414 | 397,879 | 397.2 K to 397.9 K (+0.17 %) |
| Apr 26 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Sell | S | 40.26 | 10,959 | 441,182 | 397,199 | 408.2 K to 397.2 K (-2.68 %) |
| Apr 26 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Buy | M | 2.08 | 10,959 | 22,795 | 408,158 | 397.2 K to 408.2 K (+2.76 %) |
| Apr 19 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Option Exercise | M | 2.08 | 6,000 | 12,480 | 151,424 | |
| Apr 19 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Option Exercise | M | 2.08 | 653 | 1,358 | 239,132 | |
| Apr 19 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Option Exercise | M | 2.08 | 4,940 | 10,275 | 239,785 | |
| Apr 19 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Buy | M | 2.08 | 6,000 | 12,480 | 397,199 | 391.2 K to 397.2 K (+1.53 %) |
| Apr 19 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Sell | S | 40.00 | 653 | 26,121 | 391,199 | 391.9 K to 391.2 K (-0.17 %) |
| Apr 19 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Buy | M | 2.08 | 653 | 1,358 | 391,852 | 391.2 K to 391.9 K (+0.17 %) |
| Apr 19 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Sell | S | 40.29 | 4,940 | 199,039 | 391,199 | 396.1 K to 391.2 K (-1.25 %) |
| Apr 19 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Buy | M | 2.08 | 4,940 | 10,275 | 396,139 | 391.2 K to 396.1 K (+1.26 %) |
| Apr 13 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Option Exercise | M | 2.08 | 15,000 | 31,200 | 157,424 | |
| Apr 13 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Buy | M | 2.08 | 15,000 | 31,200 | 391,199 | 376.2 K to 391.2 K (+3.99 %) |
| Apr 13 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Option Exercise | M | 2.08 | 7,000 | 14,560 | 229,899 | |
| Apr 13 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Buy | M | 2.08 | 7,000 | 14,560 | 7,000 | 0 to 7 K |
| Apr 12 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Option Exercise | M | 2.08 | 15,267 | 31,755 | 244,725 | |
| Apr 12 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Option Exercise | M | 2.08 | 22,794 | 47,412 | 259,992 | |
| Apr 12 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Option Exercise | M | 2.08 | 9,939 | 20,673 | 282,786 | |
| Apr 12 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Sell | S | 33.32 | 4,905 | 163,414 | 376,199 | 381.1 K to 376.2 K (-1.29 %) |
| Apr 12 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Sell | S | 32.29 | 10,362 | 334,566 | 381,104 | 391.5 K to 381.1 K (-2.65 %) |
| Apr 12 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Buy | M | 2.08 | 15,267 | 31,755 | 391,466 | 376.2 K to 391.5 K (+4.06 %) |
| Apr 12 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Sell | S | 34.19 | 3,742 | 127,923 | 376,199 | 379.9 K to 376.2 K (-0.98 %) |
| Apr 12 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Sell | S | 33.58 | 19,052 | 639,827 | 379,941 | 399 K to 379.9 K (-4.78 %) |
| Apr 12 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Buy | M | 2.08 | 22,794 | 47,412 | 398,993 | 376.2 K to 399 K (+6.06 %) |
| Apr 12 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Sell | S | 35.62 | 2,323 | 82,748 | 376,199 | 378.5 K to 376.2 K (-0.61 %) |
| Apr 12 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Sell | S | 34.81 | 7,616 | 265,084 | 378,522 | 386.1 K to 378.5 K (-1.97 %) |
| Apr 12 2021 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | Chief Executive Off ... | Buy | M | 2.08 | 9,939 | 20,673 | 386,138 | 376.2 K to 386.1 K (+2.64 %) |
| Mar 16 2021 | KYMR | Kymera Therapeutic ... | Booth Bruce | Director | Sell | S | 56.50 | 229,350 | 12,958,275 | 0 | 229.4 K to 0 (-100.00 %) |
| Mar 16 2021 | KYMR | Kymera Therapeutic ... | ATLAS VENTURE ASSOCIATES X, L. ... | 10% Owner | Sell | S | 56.50 | 229,350 | 12,958,275 | 0 | 229.4 K to 0 (-100.00 %) |
| Mar 16 2021 | KYMR | Kymera Therapeutic ... | Ridloff Elena | Director | Option Exercise | A | 56.10 | 40,127 | 2,251,125 | 40,127 | |
| Mar 15 2021 | KYMR | Kymera Therapeutic ... | Gollob Jared | Chief Medical Offic ... | Option Exercise | M | 1.31 | 7,800 | 10,218 | 60,007 | |
| Mar 15 2021 | KYMR | Kymera Therapeutic ... | Gollob Jared | Chief Medical Offic ... | Option Exercise | M | 1.31 | 2,200 | 2,882 | 67,807 | |
| Mar 15 2021 | KYMR | Kymera Therapeutic ... | Gollob Jared | Chief Medical Offic ... | Sell | S | 60.17 | 10,305 | 620,052 | 42,547 | 52.9 K to 42.5 K (-19.50 %) |
| Mar 15 2021 | KYMR | Kymera Therapeutic ... | Gollob Jared | Chief Medical Offic ... | Buy | M | 1.31 | 7,800 | 10,218 | 52,852 | 45.1 K to 52.9 K (+17.31 %) |
| Mar 15 2021 | KYMR | Kymera Therapeutic ... | Gollob Jared | Chief Medical Offic ... | Sell | S | 60.05 | 4,695 | 281,939 | 45,052 | 49.7 K to 45.1 K (-9.44 %) |
| Mar 15 2021 | KYMR | Kymera Therapeutic ... | Gollob Jared | Chief Medical Offic ... | Buy | M | 1.31 | 2,200 | 2,882 | 49,747 | 47.5 K to 49.7 K (+4.63 %) |
| Mar 15 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Option Exercise | M | 2.08 | 8,195 | 17,046 | 234,061 | |
| Mar 15 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Option Exercise | M | 2.08 | 1,805 | 3,754 | 242,256 | |
| Mar 15 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Sell | S | 60.17 | 8,195 | 493,096 | 0 | 8.2 K to 0 (-100.00 %) |
| Mar 15 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Buy | M | 2.08 | 8,195 | 17,046 | 8,195 | 0 to 8.2 K |
| Mar 15 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Sell | S | 60.07 | 1,805 | 108,432 | 0 | 1.8 K to 0 (-100.00 %) |
| Mar 15 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Buy | M | 2.08 | 1,805 | 3,754 | 1,805 | 0 to 1.8 K |
| Mar 08 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Option Exercise | M | 2.08 | 10,000 | 20,800 | 244,061 | |
| Mar 08 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Sell | S | 52.15 | 1 | 52 | 0 | 1 to 0 (-100.00 %) |
| Mar 08 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Sell | S | 51.28 | 2,300 | 117,936 | 1 | 2.3 K to 1 (-99.96 %) |
| Mar 08 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Sell | S | 50.46 | 7,699 | 388,482 | 2,301 | 10 K to 2.3 K (-76.99 %) |
| Mar 08 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Buy | M | 2.08 | 10,000 | 20,800 | 10,000 | 0 to 10 K |
| Mar 05 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Option Exercise | M | 2.08 | 20,000 | 41,600 | 254,061 | |
| Mar 05 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Sell | S | 45.75 | 1,100 | 50,323 | 0 | 1.1 K to 0 (-100.00 %) |
| Mar 05 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Sell | S | 45.07 | 12,019 | 541,700 | 1,100 | 13.1 K to 1.1 K (-91.62 %) |
| Mar 05 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Sell | S | 44.12 | 6,881 | 303,611 | 13,119 | 20 K to 13.1 K (-34.40 %) |
| Mar 05 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Buy | M | 2.08 | 20,000 | 41,600 | 20,000 | 0 to 20 K |
| Mar 03 2021 | KYMR | Kymera Therapeutic ... | Gollob Jared | Chief Medical Offic ... | Option Exercise | A | 48.46 | 100,000 | 4,846,000 | 100,000 | |
| Mar 03 2021 | KYMR | Kymera Therapeutic ... | Chesworth Richard | Chief Scientific Of ... | Option Exercise | A | 48.46 | 60,000 | 2,907,600 | 60,000 | |
| Mar 03 2021 | KYMR | Kymera Therapeutic ... | Chesworth Richard | Chief Scientific Of ... | Option Exercise | A | 48.46 | 60,000 | 2,907,600 | 60,000 | |
| Mar 03 2021 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Option Exercise | A | 48.46 | 140,000 | 6,784,400 | 140,000 | |
| Feb 24 2021 | KYMR | Kymera Therapeutic ... | Gollob Jared | Chief Medical Offic ... | Sell | S | 50.91 | 8,675 | 441,671 | 47,547 | 56.2 K to 47.5 K (-15.43 %) |
| Feb 24 2021 | KYMR | Kymera Therapeutic ... | Gollob Jared | Chief Medical Offic ... | Sell | S | 49.65 | 19,285 | 957,554 | 56,222 | 75.5 K to 56.2 K (-25.54 %) |
| Feb 24 2021 | KYMR | Kymera Therapeutic ... | Gollob Jared | Chief Medical Offic ... | Sell | S | 52.63 | 9,104 | 479,130 | 75,507 | 84.6 K to 75.5 K (-10.76 %) |
| Feb 22 2021 | KYMR | Kymera Therapeutic ... | Atlas Venture Fund X, L.P. | 10% Owner | Sell | J | 0.00 | 1,063,351 | 0 | 6,885,631 | 7.9 M to 6.9 M (-13.38 %) |
| Feb 19 2021 | KYMR | Kymera Therapeutic ... | Gollob Jared | Chief Medical Offic ... | Sell | S | 55.09 | 8,887 | 489,559 | 84,611 | 93.5 K to 84.6 K (-9.51 %) |
| Feb 19 2021 | KYMR | Kymera Therapeutic ... | Gollob Jared | Chief Medical Offic ... | Sell | S | 55.94 | 6,499 | 363,540 | 93,498 | 100 K to 93.5 K (-6.50 %) |
| Feb 19 2021 | KYMR | Kymera Therapeutic ... | Gollob Jared | Chief Medical Offic ... | Sell | S | 58.39 | 7,550 | 440,836 | 99,997 | 107.5 K to 100 K (-7.02 %) |
| Sep 09 2020 | KYMR | Kymera Therapeutic ... | Esposito Pamela | Director | Option Exercise | A | 29.55 | 40,127 | 1,185,753 | 40,127 | |
| Sep 09 2020 | KYMR | Kymera Therapeutic ... | Esposito Pamela | Director | Option Exercise | A | 29.55 | 40,127 | 1,185,753 | 40,127 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 180,686 | 0 | 0 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 1,000,955 | 0 | 0 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | C | 0.00 | 1,336,390 | 0 | 0 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | BVF PARTNERS L P/IL | Director | Option Exercise | A | 20.00 | 40,127 | 802,540 | 40,127 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | BVF PARTNERS L P/IL | Director | Grant | A | 20.00 | 67,791 | 1,355,820 | 181,081 | 113.3 K to 181.1 K (+59.84 %) |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 113,290 | 0 | 113,290 | 0 to 113.3 K |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | BVF PARTNERS L P/IL | Director | Grant | A | 20.00 | 389,709 | 7,794,180 | 1,017,307 | 627.6 K to 1 M (+62.10 %) |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 627,598 | 0 | 627,598 | 0 to 627.6 K |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | BVF PARTNERS L P/IL | Director | Grant | A | 20.00 | 521,193 | 10,423,860 | 1,359,109 | 837.9 K to 1.4 M (+62.20 %) |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | BVF PARTNERS L P/IL | Director | Buy | C | 0.00 | 837,916 | 0 | 837,916 | 0 to 837.9 K |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Alexandria Venture Investments ... | 10% Owner | Option Exercise | C | 0.00 | 246,305 | 0 | 0 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Alexandria Venture Investments ... | 10% Owner | Option Exercise | C | 0.00 | 500,000 | 0 | 0 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Alexandria Venture Investments ... | 10% Owner | Buy | C | 0.00 | 467,932 | 0 | 467,932 | 0 to 467.9 K |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Redmile Group, LLC | 10% Owner | Option Exercise | C | 0.00 | 2,600,740 | 0 | 0 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Redmile Group, LLC | 10% Owner | Buy | C | 0.00 | 1,630,660 | 0 | 1,630,660 | 0 to 1.6 M |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Hall Steven Edward | Director | Option Exercise | C | 0.00 | 985,220 | 0 | 0 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Hall Steven Edward | Director | Option Exercise | C | 0.00 | 2,511,198 | 0 | 0 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Hall Steven Edward | Director | Buy | C | 0.00 | 2,192,249 | 0 | 2,192,249 | 0 to 2.2 M |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Atlas Venture Fund X, L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,774,624 | 0 | 0 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Atlas Venture Fund X, L.P. | 10% Owner | Option Exercise | C | 0.00 | 1,477,832 | 0 | 0 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Atlas Venture Fund X, L.P. | 10% Owner | Option Exercise | C | 0.00 | 7,000,000 | 0 | 0 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Atlas Venture Fund X, L.P. | 10% Owner | Option Exercise | C | 0.00 | 3,000,000 | 0 | 0 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Atlas Venture Fund X, L.P. | 10% Owner | Buy | C | 0.00 | 1,112,686 | 0 | 1,112,686 | 0 to 1.1 M |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Atlas Venture Fund X, L.P. | 10% Owner | Buy | C | 0.00 | 7,196,584 | 0 | 7,948,982 | 752.4 K to 7.9 M (+956.49 %) |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Booth Bruce | Director | Option Exercise | C | 0.00 | 1,774,624 | 0 | 0 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Booth Bruce | Director | Option Exercise | C | 0.00 | 1,477,832 | 0 | 0 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Booth Bruce | Director | Option Exercise | C | 0.00 | 7,000,000 | 0 | 0 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Booth Bruce | Director | Option Exercise | C | 0.00 | 3,000,000 | 0 | 0 | |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Booth Bruce | Director | Buy | C | 0.00 | 1,112,686 | 0 | 1,112,686 | 0 to 1.1 M |
| Aug 25 2020 | KYMR | Kymera Therapeutic ... | Booth Bruce | Director | Buy | C | 0.00 | 7,196,584 | 0 | 7,948,982 | 752.4 K to 7.9 M (+956.49 %) |
| Aug 21 2020 | KYMR | Kymera Therapeutic ... | Gollob Jared | Chief Medical Offic ... | Option Exercise | A | 20.00 | 48,942 | 978,840 | 48,942 | |
| Aug 21 2020 | KYMR | Kymera Therapeutic ... | Booth Bruce | Director | Option Exercise | A | 20.00 | 40,127 | 802,540 | 40,127 | |
| Aug 21 2020 | KYMR | Kymera Therapeutic ... | Nicholson Donald William | Director | Option Exercise | A | 20.00 | 40,127 | 802,540 | 40,127 | |
| Aug 21 2020 | KYMR | Kymera Therapeutic ... | Chesworth Richard | Chief Scientific Of ... | Option Exercise | A | 20.00 | 351,119 | 7,022,380 | 351,119 | |
| Aug 21 2020 | KYMR | Kymera Therapeutic ... | Albers Jeffrey W. | Director | Option Exercise | A | 20.00 | 40,127 | 802,540 | 40,127 | |
| Aug 21 2020 | KYMR | Kymera Therapeutic ... | Mainolfi Nello | President and CEO | Option Exercise | A | 20.00 | 125,399 | 2,507,980 | 125,399 | |
| Aug 21 2020 | KYMR | Kymera Therapeutic ... | Hrustanovic Gorjan | Director | Option Exercise | A | 20.00 | 40,127 | 802,540 | 40,127 | |
| Aug 21 2020 | KYMR | Kymera Therapeutic ... | Hall Steven Edward | Director | Option Exercise | A | 20.00 | 40,127 | 802,540 | 40,127 | |
| Aug 21 2020 | KYMR | Kymera Therapeutic ... | Hedin Andrew | Director | Option Exercise | A | 20.00 | 40,127 | 802,540 | 40,127 | |
| Aug 21 2020 | KYMR | Kymera Therapeutic ... | Horobin Joanna | Director | Option Exercise | A | 20.00 | 40,127 | 802,540 | 40,127 | |
| Aug 21 2020 | KYMR | Kymera Therapeutic ... | Jacobs Bruce N. | Chief Financial Off ... | Option Exercise | A | 20.00 | 32,904 | 658,080 | 32,904 |
Page: 1